Electroencephalographia as Predictor of Effectiveness HD-tDCS in Neuropathic Pain: Machine Learning Approach

April 19, 2021 updated by: Suellen Marinho Andrade, Federal University of Paraíba

EEG as Predictor of Effectiveness of HD-tDCS in Treatment of Neuropathic Pain After Brachial Plexus Injury: Machine Learning Approach

Contextualization: Neuropathic pain is a complication present in the clinical picture of patients with traumatic Brachial Plexus injury (BPI). It is characterized by high intensity, severity and refractoriness to clinical treatments, resulting in high disability and loss of quality of life. Due to loss of afferent entry, it causes cortical and subcortical alterations and changes in somatotopic representation, from inadequate plastic adaptations in the Central and Peripheral Nervous System, one of the therapies with potential benefit in this population is the Transcranial High Definition Continuous Current Stimulation (HD-tDCS). Thus, by using connectivity-based response prediction and machine learning, it will allow greater assurance of efficiency and optimization of the application of this therapy, being directed to patients with greater potential to benefit from the application of this approach. Objective: Using connectivity-based prediction and machine learning, this study aims to assess whether baseline EEG related characteristics predict the response of patients with neuropathic pain after BPI to the effectiveness of HD-tDCS treatment. Materials and methods: A quantitative, applied, exploratory, open-label response prediction study will be conducted from data acquired from a pilot, triple-blind, cross-over, placebo-controlled, randomized clinical trial investigating the efficacy of applying HD-tDCS to patients with neuropathic brachial plexus trauma pain. Participants will be evaluated for eligibility and then randomly allocated into two groups to receive the active HD-tDCS or simulated HD-tDCS. The primary outcome will be pain intensity as measured by the numerical pain scale. Participants will be invited to participate in an EEG study before starting treatment. Clinical improvement labels used for machine learning classification will be determined based on data obtained from the clinical trial (baseline and post-treatment evaluations). The hypothesis adopted in this study is that the response prediction model constructed from EEG frequency band pattern data collected at baseline will be able to identify responders and non-responders to HD-tDCS treatment.

Study Overview

Detailed Description

Using connectivity-based prediction and machine learning, the objective is to assess whether characteristics related to baseline EEG predict the response of patients with neuropathic pain after BPI to the effectiveness of HD-tDCS treatment. An observational, retrospective cohort study will be carried out, of predictive response with a quantitative approach, of an applied nature, of an exploratory and open-label type, related to the efficacy of HD-tDCS4x1 in patients with neuropathic pain due to BPI, from an analysis of data obtained from a pilot, placebo-controlled, triple-blind, randomized, crossover type clinical trial, in accordance with the CONSORT guidelines, which will investigate the effectiveness of treatment with HD-tDCS.

Study Type

Observational

Enrollment (Anticipated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Paraíba
      • João Pessoa, Paraíba, Brazil, 58051-900
        • Federal University of Paraíba,Department of Psychology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants in a triple-blind clinical trial, based on free demand by the Laboratory of Neuroscience and aging studies at the UFPB and through access to a database with the information of these patients, linked to the Institute of Neurology and Neurosurgery of Paraíba. Patients diagnosed with neuropathic pain due to brachial plexus injury according to clinical history, physical examination and complementary. The diagnosis will be based on clinical and neurophysiological criteria, according to protocols and recommendations of Guidelines of the American Academy of Neurology. Also, it will be based on clinical evidence of loss of post-traumatic sensitivity and muscle weakness involving the upper limb. And neurophysiological tests showing damage to the nerve trunks of the brachial plexus.

Description

Inclusion Criteria:

  1. Age over 18 years;
  2. Moderate to severe pain score according to the Numerical Pain Scale (4-10);
  3. Persistent pain and refractory to clinical treatment for at least 3 months;
  4. Appropriate pharmacological treatment for pain for at least 1 month before the start of the study;
  5. Not presenting contraindications for Non-Invasive Brain Stimulation;
  6. Absence of concomitant diseases of the Central Nervous Sistem or Peripheral Nervous Sistem.

Exclusion Criteria:

  1. Failure to sign the informed consent form;
  2. Missing two consecutive or three alternate sessions during treatment;
  3. Developing a disabling condition that prevents further participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HD-tDCS4x1
All data will be acquired from patients of the triple-blind clinical trial that will investigate the effectiveness of treatment for neuropathic pain after brachial plexus injury with HD-tDCS. There will be collection and analysis of EEG data before the clinical trial protocol, to later assess the prediction of response to the technique employed. At the end, they will be grouped into responders and non-responders to HD-tDCS, according to the numerical scale of pain, with assignments serving as targets for the analyzes with machine learning. The labels for clinical improvement used to classify machine learning will be determined based on the data obtained in the baseline and post-treatment assessments, according to similar studies. Thus, the EEG data of these patients will be retrospectively examined, identifying possible neurophysiological characteristics and biomarkers related to the frequency bands that allow predicting which patients are most likely to improve with this treatment.
5 consecutive sessions lasting 20 minutes of HD-tDCS4x1, based on previous publications (VILLAMAR et al., 2013). A list will be provided current of 2 mA, placing a central electrode (anode) on the M1 contralateral to the painful limb and the four return electrodes within a radius of 7.5 cm around, corresponding approximately to Cz, F3, T7 and P3 if the stimulation is on the side left, and Cz, F4, T8 and P4 if it is on the right, according to the International 10/20 System.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity measured using Numerical Pain Scale
Time Frame: 1 week (5 sessions)
Identification of responders and non-responders to treatment with HD-tDCS, according to the scores obtained by the patients response on the Numerical Pain Scale recorded immediately after the treatment, thus determining the functional labels for processing machine learning models. This instrument measures the intensity of pain, consisting of 11 points (0-10), 0 being counted for no pain and 10 for the worst possible pain. A reduction of two points or by 30% will be considered a clinically important minimum difference (DWORKIN et al., 2008).
1 week (5 sessions)
Neurophysiological characteristics and biomarkers recorded by EEG
Time Frame: One month
The EEG data will be retrospectively examined by comparing the two groups (responders and non-responders), identifying possible neurophysiological characteristics and biomarkers related to frequency bands and connectivity that could be characterized as possible markers of response to treatment, predicting which are most likely to respond. The examination of the cortical electrical activity using the EEG tool (BrainVision actiCHamp, Herrsching, Germany), with 32 silver chloride electrodes fixed according to the International System 10-20, by means of an adjustable cap, containing holes that will allow the contact of the electrode with the scalp. The prefrontal, frontal, parietal, temporal and occipital regions will be monitored bilaterally (Fp1, Fp2, F3, F4), temporal (F7, F8, T3, T4, T5, T6), central (C3, C4, Cz) and parieto-occipital (P3, P4, P7, P8, O1, O2), in the condition of silence, with eyes closed, for five minutes each, totaling 10 minutes of collection for each participant.
One month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 15, 2021

Primary Completion (Anticipated)

December 15, 2021

Study Completion (Anticipated)

June 15, 2022

Study Registration Dates

First Submitted

April 5, 2021

First Submitted That Met QC Criteria

April 19, 2021

First Posted (Actual)

April 21, 2021

Study Record Updates

Last Update Posted (Actual)

April 21, 2021

Last Update Submitted That Met QC Criteria

April 19, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

Clinical Trials on Neurostimulation (High Definition - transcranial Direct Current Stimulation) HD-tDCS

Subscribe